01
CEO | Founder
Brent Chamberlain
Biopharma and quality
MYKITO SCIENCESBuilt to make chitosan
dependable.
Mykito Sciences exists to unlock the industrial potential of chitosan by replacing constrained animal supply with controlled, non-animal production and material engineering.
The opportunity was clear:
better chitosan was missing.
“The molecule was always right. It was the shell that was holding it back.”
Mykito Sciences was formed in 2017 after founder Brent Chamberlain recognized that mainstream adoption was being constrained by the absence of high-purity, consistent non-animal chitosan.
The company began with the potential of fungal fermentation to create repeatable material without the beta-glucans, heavy metals and other contaminants that can complicate conventional supply.
Today, Mykito connects source platforms, molecular engineering and application-ready formats to help customers build products—not merely evaluate another raw ingredient.
The goal is simple: manufacture chitosan around the specification, not around what a crustacean shell happens to yield.
100% focused
on chitosan.
Mykito brings together deep experience in biopharma, quality, purification, fermentation, process engineering, venture building and chitosan commercialization.
02
COO | CFO
Mike Dost
25-year venture capital background
BDC Capital · Octane Venture Partners
03
VP Product & Attribute Sciences
Dr. Jon Huddleston
46 years of purification and analytical expertise
University of Birmingham · Merck
04
VP Business Development
Jerome Delay
10 years of chitosan experience and 25 years of business development experience
Alpha Chitin · FlexLink
05
VP Process Sciences & Engineering
Gary Lesnicki
51 years of fermentation expertise
Lundbeck · Alder Biopharmaceuticals
HOW WE WORK
Source responsibly.
Build supply around renewable, non-animal biological inputs.
Specify precisely.
Control the attributes that determine performance in the final application.
Scale practically.
Deliver formats and formulations that move customer programs forward.